博安生物（06955.HK）今日盘中大跌5.22%，引发市场关注。这一跌幅主要源于公司最新发布的2025年中期业绩报告。
根据公司公告，博安生物截至2025年6月30日的六个月内，股东应占溢利为2051.4万元人民币，同比大幅下降66.74%。尽管公司收入同比增长8.39%至3.93亿元人民币，但净利润的显著下滑仍然令投资者感到失望。每股基本盈利降至0.04元人民币，公司决定不派发中期股息。
值得注意的是，博安生物的主要产品销售仍然保持增长。公告显示，博优诺®、博优倍®及博洛加®等产品的销售较去年同期增长15.9%，达到3.85亿元人民币。然而，这一增长似乎未能抵消其他方面的成本上升或收益下降。市场将密切关注公司后续的经营策略及业绩表现，以评估其长期发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.